Mark Stejbach

Mark Stejbach

Direktör/Styrelseledamot på
Indivior Ltd.

Förmögenhet: 975 674 $ per 2026-05-31

62 år
Health Technology
Consumer Services
Finance

Profil

Mr. Mark P.
Stejbach
is an Independent Non-Executive Director at Indivior Pharmaceuticals, Inc. and an Independent Non-Executive Director at Indivior Ltd. He is on the Board of Directors at Indivior Pharmaceuticals, Inc., Indivior Ltd. and Nirsum Laboratories, Inc. Mr. Stejbach was previously employed as an Independent Non-Executive Director by Flexion Therapeutics, Inc., a Chief Commercial Officer & Senior Vice President by Alkermes Plc, a Chief Commercial Officer by Tengion, Inc., a Principal by Biogen Idec MA, Inc., and a Vice President-Managed Care Marketing by Merck & Co., Inc. He also served on the board at Commonwealth National Fund, Inc. He received his undergraduate degree from Virginia Polytechnic Institute & State University and an MBA from The Wharton School of the University of Pennsylvania.

Kända innehav i offentliga företag

FöretagDatumAntal aktierVärderingVärderingsdatum
0,02 %
2026-05-13 27 087 ( 0,02 % ) 975 674 $ 2026-05-31

Aktiva positioner av Mark Stejbach

FöretagPositionStart
Direktör/Styrelseledamot 2021-03-24
Direktör/Styrelseledamot -

Tidigare kända positioner av Mark Stejbach

FöretagPositionSlut
FLEXION THERAPEUTICS, INC. Direktör/Styrelseledamot 2021-11-19
ALKERMES PLC Företagsledare/Principal 2018-10-01
TENGION, INC. Offentlig kommunikationskontakt 2012-01-01
Direktör/Styrelseledamot 2011-01-01
MERCK & CO., INC. Företagsledare/Principal 2008-07-01
Se detaljerna i Mark Stejbachs erfarenhet

Mark Stejbachs utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

95

Första gradens relationer

10

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag10

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Consumer Services

Finance

Health Technology

  1. Börsen
  2. Insiders
  3. Mark Stejbach